EGFR and non-small cell lung carcinoma: Molecular diagnosis for activating “hot-spot” mutations in EGFR exons 18 to 21 is recommended in all patients with advanced NSCLC of a non-SCC subtype since TKI therapy provides significant improvement in survival and quality of life [9].